GlassScriptPhysician profile
Matthew Dean Jackson
NPI 1528590460
$1,672.28
in general payments reported to CMS, 2019-2025
19 companies · $490 in 2025
The $490 reported for 2025 was more than what 93% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $154 · 2022: $294 · 2023: $252 · 2024: $483 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191 · Debt Forgiveness: $34.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.74 |
| Debt Forgiveness | $34.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $214.86 | 2024-2025 | Qelbree |
| Ironshore Pharmaceuticals INC. | $206.58 | 2022-2024 | Jornay Pm |
| Collegium Pharmaceutical, INC. | $168.32 | 2025 | Jornay Pm |
| Corium, LLC | $158.55 | 2022-2025 | Azstarys |
| Pfizer INC. | $156.95 | 2022-2025 | |
| Baxter Healthcare | $108.95 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.43 | 2021-2022 | |
| Glaxosmithkline, LLC. | $102.03 | 2022-2024 | Bexsero, Pediarix, Menveo |
| Regeneron Healthcare Solutions, INC. | $89.94 | 2024-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $76.88 | 2021-2024 | Vaxelis, Vaxneuvance, Gardasil 9 |
| Welch Allyn | $57.62 | 2021 | |
| Sanofi Pasteur INC. | $51.11 | 2023-2025 | |
| Qol Medical, LLC | $35.57 | 2022-2025 | Sucraid |
| Tris Pharma INC | $35.35 | 2024 | Dyanavel Xr |
| Sobi, INC | $30.94 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $29.26 | 2023 | Valtoco |
| Astrazeneca Pharmaceuticals LP | $17.21 | 2024 | Flumist Quadrivalent |
| Ibsa Pharma INC. | $15.63 | 2022 | |
| Aytu Biopharma, INC. | $14.10 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.